Why the study?
Does management in a heart failure specialty clinic improve adherence to ACC/AHA guideline-directed medical therapy compared to a family medicine clinic in patients with chronic systolic heart failure?
Does management in a heart failure specialty clinic improve adherence to ACC/AHA guideline-directed medical therapy compared to a family medicine clinic in patients with chronic systolic heart failure?
While heart failure specialty clinics achieve higher beta-blocker prescription rates, achieving target doses of guideline-directed medical therapy remains a challenge across both specialty and primary care settings.
Target dosing remains challenging in both settings; observational data leave open whether specialty clinics improve overall GDMT adherence.
UNLABELLED: Guidelines have been published for management of chronic systolic heart failure to reduce patient morbidity and mortality. OBJECTIVE: A quality review of the heart failure medical therapy for a community family medicine residency program clinic and a multidisciplinary heart failure specialty clinic was performed to compare adherence to ACC/AHA heart failure guidelines, with regard to medications and in titrating to recommended target doses. METHODS: The study was a retrospective chart review and data collected included name and dose of any ACEI, beta-blocker, ARB, or other medication addressed in the guidelines. RESULTS: Specialty clinic patients had significantly lower systolic blood pressures and ejection fractions. Significantly more patients were prescribed beta-blockers in the specialty clinic population (98% vs 80%, p<0.05). Both patient populations had very low rates of reaching target beta-blocker doses (15% vs 21%, p=0.27). More patients in the family medicine clinic reached target doses of ACEI (64% vs 49%, p<0.05) and ARBs (67% vs 35%, p<0.05). CONCLUSIONS: This study revealed the vast majority of patients in either a community family medicine residency program or heart failure specialty clinic were prescribed ACEI or ARB, and beta-blockers. However, achieving target doses should continue to be an important goal for practitioners.
No takes yet. Share an insight, caveat, or question.
Dehoney et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: